Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enzon Pharmaceuticals has submitted an application to the FDA to begin the clinical testing of HIF-1alpha, an antagonist drug that targets multiple cancer processes, including solid tumors.
Subscribe to our email newsletter
“The filing of HIF-1alpha, our fourth IND submission in 2006, demonstrates our strong commitment to delivering on our promises and developing a differentiated cancer portfolio,” said Jeffrey Buchalter, CEO of Enzon.
The target HIF-1alpha functions as a key regulator of a large number of genes important in cancer biology, such as angiogenesis, cell proliferation, apoptosis and cell invasion. HIF-1alpha protein is too low in normal cells, but reaches high intracellular concentrations in a variety of cancers and is strongly correlated with poor prognosis and resistance to therapy. Drugs targeting HIF-1alpha therefore have the potential to target multiple cancer processes.
Enzon licensed the HIF-1alpha antagonist from Santaris in July 2006 along with the Survivin antagonist, and six additional proprietary RNA antagonist candidates, all directed against novel cancer targets selected by Enzon.